Literature DB >> 23482773

A population-based series of ovarian carcinosarcomas with long-term follow-up.

Gunnar Paulsson1, Solveig Andersson, Bengt Sorbe.   

Abstract

AIM: The aim of the present study was to evaluate a consecutive series of ovarian carcinosarcomas with regard to prognosis, treatment and prognostic factors. PATIENTS AND METHODS: A consecutive series of 81 ovarian carcinosarcomas from two well-defined geographic regions were studied with regard to survival, type of primary and adjuvant therapy and prognostic factors. All patients but one underwent primary surgery and some patients also received adjuvant chemotherapy (platinum-based) alone or in combination with radiotherapy. Univariate and multivariate Cox proportional regression analysis was used. Survival was analyzed by the Kaplan-Meier technique and differences were assessed by the log-rank test.
RESULTS: The mean age of the patients was 73 years. Fifty-one patients received adjuvant chemotherapy and nine patients pelvic irradiation. The 5-year overall survival rate was 10%. Adjuvant therapy (any type) and six completed cycles of chemotherapy were highly significant factors with regard to improved overall survival rate. The only significant tumor-associated prognostic factor was the International Federation of Gynecology and Obstetrics (FIGO) grade of the tumor. FIGO stage, site of metastatic spread, tumor size, histology, DNA ploidy, and tumor necrosis were non-significant factors. Therapy was rather well-tolerated and 29 patients (57%) completed at least six cycles of adjuvant chemotherapy.
CONCLUSION: Adjuvant and completed chemotherapy according to the treatment plan were the most important prognostic factors. FIGO grade (grade 3 vs. 1-2) of the epithelial component of the tumor was also a significant prognostic factor in multivariate Cox analysis.

Entities:  

Mesh:

Year:  2013        PMID: 23482773

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Ovarian carcinosarcoma: a case report, diagnosis, treatment and literature review.

Authors:  G M Makris; C Siristatidis; M J Battista; C Chrelias
Journal:  Hippokratia       Date:  2015 Jul-Sep       Impact factor: 0.471

2.  Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.

Authors:  Ibrahim Yalcin; Mehmet Mutlu Meydanli; Ahmet Taner Turan; Salih Taskin; Mustafa Erkan Sari; Tayfun Gungor; Ozgur Akbayir; Ali Ayhan
Journal:  Int J Clin Oncol       Date:  2017-11-16       Impact factor: 3.402

3.  Management of a rare ovarian carcinosarcoma: A case report and literature review.

Authors:  Jun Fu
Journal:  Exp Ther Med       Date:  2022-07-19       Impact factor: 2.751

4.  Ovarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival.

Authors:  Amelia M Jernigan; Amanda Nickles Fader; Benjamin Nutter; Peter Rose; Jill H Tseng; Pedro F Escobar
Journal:  Obstet Gynecol Int       Date:  2013-05-27

5.  Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma.

Authors:  Graziela Zibetti Dal Molin; Carina Meira Abrahão; Robert L Coleman; Fernando Cotait Maluf
Journal:  Gynecol Oncol Res Pract       Date:  2018-08-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.